Navigation Links
Sinovac Reports Third Quarter 2008 Unaudited Financial Results
Date:11/18/2008

BEIJING, Nov. 18 /PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading developer and provider of vaccines in China, today announced the Company's financial results for the three-month and nine-month periods ended September 30, 2008.

    Highlights
    -- Sales year-to-date increased 40% year-over-year to $34.1 million
    -- Operating income year-to-date rose 22.5% year-over-year to $12.4
       million
    -- Net income year-to-date maintained at same level year-over-year at $5.6
       million, inclusive of 25% income tax rate for 2008 versus 15% for 2007
    -- Cash and cash equivalents increased 9% to $20.5 million, compared to
       the second quarter of 2008, due to improved accounts receivable
       collection

Mr. Weidong Yin, Chairman, President and CEO, commented, "Our nine month sales growth was in line with our previously stated objective to increase sales by 35% to 45% over the prior year. As we continue to execute our business plan, management is very confident that the Company is on track to achieve the projected full year sales growth rate for 2008. At the same time, we have increased our investment in research and development in order to focus on long-term growth. The development of a vaccine against human enterovirus 71 (EV 71), which causes hand, foot, and mouth disease, is one of our R&D programs that demonstrate our strategy to develop novel vaccines. We expect this vaccine to become another top-selling flagship product similar to Healive(R), once it is developed and commercialized. Even though we are currently facing challenging financial markets, management continues to prudently execute its long-term growth strategy designed to maximize shareholder value."

Three Months Ended September 30, 2008

For the third quarter 2008, sales were $8.8 million, compared to $10.8 million in the third quarter 2007. The year-over-year change in sales reflected the Company's strategy of heavily promoting Healive in the private market in the first half of the year, as the Company expects the size of the public market for the hepatitis A vaccine to possibly increase significantly and the size of the private market may decrease in the second half of the year.

During the third quarter of 2008, Sinovac sold 1.1 million doses of Healive(R), compared to 1.53 million doses for the same period of 2007. Following the launch of Anflu(R) in early September, Sinovac sold 663,000 doses during the third quarter of 2008, compared to 1.07 million doses for the same period of the prior year. During the third quarter of 2008, Sinovac sold 28,000 doses of Bilive(R), compared to nil doses in the prior year period. As mentioned previously, the year-over-year change in sales was in line with the Company's sales and marketing strategy. For the third quarter for 2008, Healive, Anflu, and Bilive as a percentage of sales represented 78%, 19.5% and 2.5%, respectively.

Gross profit for third quarter 2008 was $7.1 million, with a gross margin of 81.0%, compared to $9.2 million and 84.7% for the same period of 2007. The change in gross margin as a percentage of sales was primarily attributable to the product sales mix during the third quarter of 2008.

Total operating expenses for the third quarter 2008 were $4.8 million, compared to $5.1 million in the same period 2007. Selling, general and administrative expenses for the third quarter of 2008 were $3.8 million, compared to $4.8 million in the same period of 2007. SG&A expenses as a percentage of sales represented 43.3% in the third quarter of 2008, compared to 44.0% in the same period in the prior year.

Gross expenditures on research and development expenses for the third quarter of 2008 were $812,000, compared to $221,000 in the same period of 2007. The increased R&D expenses in the current quarter were mainly incurred for the advancement of its vaccine candidates in the preclinical development pipeline inclusive of its vaccine against human enterovirus 71 (EV 71), which causes hand, foot, and mouth disease (HFMD).

Operating income was $2.3 million for the third quarter of 2008, compared to $4.0 million in the same period of 2007. The year-over-year variance in operating income reflected lower vaccine sales in the current period and moderately higher R&D expenses.

Net income for the third quarter of 2008 included $190,000 of interest and financing expenses, $911,000 of income taxes, $58,000 interest and other income and $530,000 of minority interest. Net income for the same period of 2007 included $116,000 of interest and financing expenses, $758,000 of income taxes, $41,000 interest and other income and $1.0 million of minority interest. Net income for the third quarter of 2008 was $740,000, or $0.02 per diluted share, compared to $2.2 million, or $0.05 per diluted share, in the same period of 2007.

During the third quarter of 2008, Sinovac Beijing continued the preparation of its application to the Chinese government for the High and New Technology Enterprises (HNTE) status. HNTEs are entitled to the preferential income tax rate of 15% compared to the unified income tax rate of 25% effective January 1, 2008. Prior to 2008, Sinovac Beijing was subject to the preferential income tax rate of 15% as a HNTE. Given that it is uncertain whether Sinovac will eventually be approved for HNTE status, Sinovac Beijing account for its current and deferred income tax utilizing the enacted statutory tax rate of 25% as the applicable enterprises income tax rate for 2008.

In the event that Sinovac Beijing reconfirms its HNTE status in accordance with the HNTE guidelines, a 15% corporate income tax rate would be retroactive to January 1, 2008, according to the newly enacted Enterprises Income Tax Law. Assuming HNTE is received, the impact on the results of operations for the nine months ended September 30, 2008 would include a $1,667,726 decrease in the provision of the current income tax with a corresponding reduction in the income tax liability and a $905,687 increase in deferred income tax expense with an offset to deferred income tax assets. The change of rate will be recorded in the period that changes occur.

As of September 30, 2008, Sinovac's cash and cash equivalents totaled $20.5 million, compared to $18.8 million as of June 30, 2008. The 9% increase in cash and cash equivalents compared to the second quarter of 2008 was primarily attributable to improved accounts receivables collection.

Nine Months Ended September 30, 2008

For the nine months ended September 30, 2008, sales reached $34.1 million, compared to $24.3 million for the same period of 2007, representing a 40% growth rate.

During the nine months ended September 30, 2008, Sinovac sold 5.3 million doses of Healive(R), compared to 4.1 million doses for the same period of 2007. The Company sold 234,000 doses of Bilive(R) during the 2008 period, compared to nil doses in the prior year period. As mentioned previously, the year- over-year change in sales was in line with the Company's sales and marketing strategy. For the first nine months of 2008, Healive, Anflu, and Bilive as a percentage of sales represented 91%, 5% and 4%, respectively.

Gross profit for nine months ended September 30, 2008 was $28.8 million, with a gross margin of 84.4%, compared to $20.7 million and 85.2% for the same period of 2007. The change in gross margin as a percentage of sales was primarily attributable to the product sales mix during the 2008 period.

Total operating expenses for the nine months ended September 30, 2008 were $16.4 million, compared to $10.6 million for the same period 2007. Selling, general and administrative expenses for the nine months ended September 30, 2008 were $13.4 million, compared to $9.5 million in the same period of 2007. SG&A expenses as a percentage of sales represented 39% in the 2008 period, compared to 41.0% in the same period in the prior year.

Gross expenditures on research and development expenses for the nine months ended September 30, 2008 were $2.4 million, including trial production costs for Panflu, compared to $611,000 in the same period of 2007.

Operating income was $12.5 million for the nine months ended September 30, 2008, compared to $10.2 million in the same period of 2007. The year-over- year variance in operating income reflected lower vaccine sales in the current period and moderately higher R&D expenses.

Net income for the nine months ended September 30, 2008 included $747,000 of interest and financing expenses, $3.2 million of income taxes, $37,000 of other income and $2.8 million of minority interest. Net income for the same period of 2007 included $295,000 of interest and financing expenses, $1.9 million of income taxes, $301,000 interest and other income and $2.6 million of minority interest. Net income for the nine months ended September 30, 2008 was $5.6 million, or $0.13 per diluted share, compared to $5.7 million, or $0.14 per diluted share, in the same period of 2007.

Recent Developments

In September 2008, the Company initiated development of a vaccine against human enterovirus 71 (EV 71), which causes hand, foot, and mouth disease. The development of a vaccine against EV 71 is in compliance with our R&D strategy to develop novel vaccines. Since there is no vaccine against this disease at the moment, the Company expects this vaccine to join Healive(R) as a potential blockbuster product.

The Company participated in the China's National R&D Program's selection and evaluation process. Sinovac was selected by the government to take charge of the research and development program for the varicella (chickenpox) vaccine. As an acute infectious disease, varicella often breaks out among the pediatric population and can lead to serious conditions such as pneumonia, encephalitis, and even death. This disease leads to serious symptoms among adult as well. The fatality rate in adults is as high as 30-40 times that of children between 5-9 years old. According to a report by the Children Hospital of Shanghai, current incidence rate among children is four times greater than rates reported in the 1980s. The domestic market in China is in a development phase with an annual demand of 10 million doses. Once the vaccine is successfully launched, Sinovac would provide the Chinese market with a new vaccine against varicella and the herpes zoster virus.

During the third quarter, Sinovac advanced the development of its split pandemic influenza vaccine. The Company completed volunteer enrollment and dosing in its Phase II double-blind trial of the split pandemic influenza vaccine. The second shot was administered to 472 healthy volunteers in September, inclusive of 263 adolescents, 138 pediatrics and 71 geriatrics. The vaccination process to volunteers has been completed and the Company is currently collecting data and preparing the analysis. It is anticipated that the preliminary results will be available in early 2009.

In October 2008, Sinovac was named to the Deliotte Technology Fast 50 China 2008 based on its high growth rate of 290% over the past three years. The ranking recognizes the 50 fastest growing life sciences, technology, media and telecommunications in China.

Conference Call Details

The Company will host a conference call on Tuesday, November 18, 2008 at 8:00 p.m. ET to review the Company's third quarter financial results for the period ended September 30, 2008 and provide an update on recent corporate developments. To access the conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international). A replay of the call will be available from 11:00 p.m. ET on November 18 until December 2, 2008. To access the replay, please dial 1-877-660-6853 (USA) or 1-201-612-7415 (international) and reference the account number 3055 and the access code 303493. A live audio webcast of the call will also be available from the Investors section on the corporate web site at http://www.sinovac.com . A webcast replay can be accessed on the corporate website beginning November 18, 2008 and the replay will remain available for 30 days.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac is currently developing universal pandemic influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, http://www.sinovac.com . To be added to our distribution list, please email: info@sinovac.com .

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.


    SINOVAC BIOTECH LTD.
    Consolidated Balance Sheets
    (Unaudited)
    (Expressed in U.S. Dollars)
                                              September 30,      December 31,
                                                      2008              2007
    ASSETS

    Current assets
      Cash and cash equivalents                $20,552,500       $17,071,497
      Accounts receivable - net                 24,961,357        16,983,892
      Inventories                                8,014,050         3,745,957
      Prepaid expenses and deposits                750,191           800,840
      Deferred tax assets                        1,293,131           579,703

    Total current assets                        55,571,229        39,181,889

    Restricted cash                                  1,643               846

    Property, plant and equipment               19,479,227        15,879,391
    Long-term prepaid expenses and deposits        225,255           298,731

    Deferred tax asset                             971,085           693,053

    Licenses and permits                         1,189,599         1,394,052

    Total assets                               $77,438,038       $57,447,962

    LIABILITIES AND STOCKHOLDERS' EQUITY

    Current liabilities
      Loans payable                             $3,646,920        $6,836,110
      Accounts payable and accrued
       liabilities                              12,234,749         9,522,818
      Due to related parties                        46,971            46,971
      Dividends payable to minority
       Interest shareholder
       of Sinovac Beijing                          115,661         3,000,459
      Deferred research grants                   1,193,470         1,038,396

    Total current liabilities                   17,237,771        20,447,754

    Deferred government grants                   2,917,536         2,734,444
    Loan payable                                 3,646,920         1,367,222
    Long - term debt                             6,564,456         4,101,666

    Total liabilities                           23,802,227        24,546,420

    Minority interest                            5,787,345         2,897,687

    Commitments and contingencies

    STOCKHOLDERS' EQUITY

    Preferred stock                                     --                --
      Authorized 50,000,000 shares at par
       value of $0.001 each
       Issued and outstanding: nil
    Common stock                                    42,881            40,305
      Authorized: 100,000,000 shares at
       par value of $0.001 each
       Issued and outstanding:  42,881,023
       (2007 - 40,305,028)
    Subscriptions received                          20,060             9,170
    Additional paid in capital                  42,021,057        32,109,997
    Accumulated other comprehensive income       4,240,457         1,956,456
    Dedicated reserves                           2,999,396         2,999,396
    Accumulated deficit                         (1,475,385)       (7,111,469)

    Total stockholders' equity                  47,848,466        30,003,855

    Total liabilities and stockholders'
     equity                                    $77,438,038       $57,447,962



    SINOVAC BIOTECH LTD.
    Consolidated Statements of Income and Comprehensive Income
    Three Months and Nine months Ended September 30, 2008 and 2007
    (Unaudited)
    (Expressed in U.S. Dollars)
                                                     Three months ended
                                                        September 30
                                                   2008              2007

    Sales                                       $8,753,671        $10,828,020

    Cost of sales - (exclusive of
     depreciation of land-use rights and
     amortization of licenses and permits
     of $104,490 (2007 - $93,095) for
     three months and  $307,065 (2007-
     279,988) for nine months)                   1,658,862          1,655,589

    Gross profit                                 7,094,809          9,172,431
    Selling, general and administrative
     expenses                                    3,791,916          4,763,054

    Research and development expenses -
     net of $17,110 (2007- $74,563) for three
     months and $147,958 (2007- $441,974)
     for nine months in government
     research grants                               811,901            220,811

    Depreciation of property, plant and
     equipment  and amortization of
     licenses and permits                          178,404            146,475

    Total operating expense                      4,782,221          5,130,340

    Operating income                             2,312,588          4,042,091

    Interest and financing expenses               (189,935)          (115,588)

    Interest income and other income
     (expenses)                                     58,456             40,651

    Income before income taxes and
     minority interest                           2,181,109          3,967,154

    Income taxes recovery (expense)
       - Current                                (1,005,174)          (817,000)
       - Deferred                                   94,028             59,375

    Income before minority interest              1,269,963          3,209,529

    Minority interest share of earnings            530,084          1,019,377

    Net income                                     739,879          2,190,152

    Other comprehensive income
    Foreign currency translation adjustment         40,797            333,325
    Comprehensive income                          $780,676         $2,523,477
    Earnings per share - basic                       $0.02              $0.05
                              - diluted              $0.02              $0.05
    Weighted average number of shares of
      common stock outstanding
        - Basic                                 42,873,511         40,268,030
        - Diluted                               43,142,788         40,624,439


                                                     Nine months ended
                                                       September 30
                                                  2008              2007

    Sales                                      $34,137,101        $24,339,241

    Cost of sales - (exclusive of
     depreciation of land-use rights and
     amortization of licenses and permits
     of $104,490 (2007 - $93,095) for
     three months and  $307,065 (2007-
     279,988) for nine months)                   5,320,667          3,587,193

    Gross profit                                28,816,434         20,752,048
    Selling, general and administrative
     expenses                                   13,408,452          9,485,980

    Research and development expenses -
     net of $17,110 (2007- $74,563) for three
     months and $147,958 (2007- $441,974)
     for nine months in government
     research grants                             2,408,745            611,210

    Depreciation of property, plant and
     equipment  and amortization of
     licenses and permits                          526,117            474,818

    Total operating expense                     16,343,314         10,572,008

    Operating income                            12,473,120         10,180,040

    Interest and financing expenses               (747,496)          (294,657)

    Interest income and other income
     (expenses)                                    (36,685)           301,301

    Income before income taxes and
     minority interest                          11,688,939         10,186,684

    Income taxes recovery (expense)
       - Current                                (4,229,613)        (1,872,944)
       - Deferred                                  991,461            (58,696)

    Income before minority interest              8,450,787          8,255,044

    Minority interest share of earnings          2,814,703          2,597,913

    Net income                                   5,636,084          5,657,131

    Other comprehensive income
    Foreign currency translation adjustment      2,284,001            797,483
    Comprehensive income                        $7,920,085         $6,454,614
    Earnings per share - basic                       $0.13              $0.14
                              - diluted              $0.13              $0.14
    Weighted average number of shares of
      common stock outstanding
        - Basic                                 42,299,187         40,243,657
        - Diluted                               42,638,584         40,523,937



    SINOVAC BIOTECH LTD.
    Consolidated Statements of Cash Flows
    Three Months and Nine Months Ended September 30, 2008 and 2007
    (Unaudited)
    (Expressed in U.S. Dollars)
                                               Three Months ended September 30
                                                     2008               2007

    Cash flows from (used in) operating activities
      Net Income for the period                    $739,879        $2,190,152
      Adjustments to reconcile net income
       to net cash used by operating activities:
      - deferred income taxes                       (94,028)          (59,375)
      - loss on disposal of equipment                 2,249               997
      - stock-based compensation                     16,635            20,596
      - provision for doubtful debts                408,289         1,027,305
      - depreciation of property, plant
       and equipment, and   amortization
       of licenses                                  517,751           329,084
      - research and development
       expenditures qualified for
       government grant                             (16,829)           11,912
      - minority interests                          530,084         1,019,377
     Change in other assets and
      liabilities
      - accounts receivable                       4,718,247        (5,426,779)
      - inventories                              (1,620,126)         (699,334)
      - prepaid expenses and deposits               273,079           (14,444)
      - accounts payable and accrued
       liabilities                               (2,168,844)        1,338,136
    Net cash provided by (used in)
     operating activities                         3,306,386          (262,373)

    Cash flows from (used in) financing
     activities
      Loan repayment                             (3,572,010)         (655,061)
      Loan proceeds                               2,143,206         1,302,812
      Proceeds from issuance of common stock             --             2,621
      Payment to release shares in escrow                --           994,333
      Proceeds from shares subscribed                20,060                --
      Dividends paid to minority interest
       shareholder in Sinovac Beijing                    --                --
      Government grant received                     143,626           138,173
    Net cash provided by (used in)
     financing activities                        (1,265,118)        1,782,878

    Cash flows from (used in) investing
     activities
      Restricted cash                               434,196             1,303
    Acquisition of property, plant and
     equipment                                   (1,046,849)       (1,159,754)
    Net cash used in investing activities          (612,653)       (1,158,451)

    Exchange effect on cash and equivalents         303,614            31,313
    Increase in cash and cash equivalents         1,732,229           393,367

    Cash and cash equivalents, beginning
     of period                                   18,820,271         9,282,369

    Cash and cash equivalents, end of
     period                                     $20,552,500        $9,675,736

      Cash paid for interest, net of
       interest capitalized                        $150,660           $66,153
      Cash paid for income taxes                 $1,502,166          $773,938
    Supplemental schedule of non-cash
     activities:
    Acquisition of property, plant and
     equipment included in accounts
     payable and accrued liabilities               $340,409          $588,979


                                                Nine months ended September 30
                                                   2008              2007
    Cash flows from (used in) operating
      activities
      Net Income for the period                 $5,636,084         $5,657,131
      Adjustments to reconcile net income
       to net cash used by operating activities:
      - deferred income taxes                     (991,461)            58,696
      - loss on disposal of equipment                2,249              4,954
      - stock-based compensation                    49,907            159,147
      - provision for doubtful debts             1,968,207          1,781,849
      - depreciation of property, plant
       and equipment, and   amortization
       of licenses                               1,298,314          1,049,275
      - research and development
       expenditures qualified for
       government grant                           (147,677)          (365,746)
      - minority interests                       2,184,703          2,597,913
     Change in other assets and liabilities
      - accounts receivable                     (8,650,832)       (11,144,117)
      - inventories                             (3,934,756)        (2,687,289)
      - prepaid expenses and deposits              188,789           (674,823)
      - accounts payable and accrued
       liabilities                               1,973,562          1,244,340
    Net cash provided by (used in)
     operating activities                          207,089         (2,318,670)

    Cash flows from (used in) financing
     activities
      Loan repayment                            (3,572,010)        (1,172,531)
      Loan proceeds                              2,143,206          1,302,814
      Proceeds from issuance of common stock     9,854,560            183,971
      Payment to release shares in escrow               --          1,394,333
      Proceeds from shares subscribed               20,060                 --
      Dividends paid to minority interest
       shareholder in Sinovac Beijing           (2,947,877)          (833,071)
      Government grant received                    214,321          3,100,694
    Net cash provided by (used in)
     financing activities                        5,712,260          3,976,210

    Cash flows from (used in) investing
     activities
      Restricted cash                                 (725)            24,029
    Acquisition of property, plant and
     equipment                                  (3,283,424)        (1,417,034)
    Net cash used in investing activities       (3,284,149)        (1,393,005)

    Exchange effect on cash and equivalents        845,803            162,369
    Increase in cash and cash equivalents        3,481,003            426,904

    Cash and cash equivalents, beginning
     of period                                  17,071,497          9,248,832

    Cash and cash equivalents, end of period   $20,552,500         $9,675,736

      Cash paid for interest, net of
       interest capitalized                       $456,665           $225,971
      Cash paid for income taxes                $2,812,129         $1,291,612
    Supplemental schedule of non-cash
     activities:
    Acquisition of property, plant and
     equipment included in accounts
     payable and accrued liabilities              $340,409           $588,979


    For more information, please contact:

     Helen G. Yang
     Sinovac Biotech Ltd.
     Phone: +86-10-8289-0088 x871
     Fax:   +86-10-6296-6910
     Email: info@sinovac.com


     Investors/Media:
     Stephanie Carrington/Janine McCargo
     The Ruth Group
     Tel:   +1-646-536-7017/7033
     Email: scarrington@theruthgroup.com
            jmccargo@theruthgroup.com

'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved


Related biology technology :

1. Sinovac Named to Deloitte Technology Fast 50 China
2. Sinovac to Participate in Two Upcoming Investor Conferences
3. Sinovacs Credit Rating Upgraded to AAZ, Second Highest Rating
4. Sinovac Biotech Holds 2007 Annual General Meeting
5. Sinovac to Present at the 2008 UBS Global Life Sciences Conference
6. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
7. Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
8. Sinovac Adjourns Annual General Meeting
9. Sinovac to Present at the Susquehanna Financial Groups Second Annual Beijing Management Summit Conference
10. Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results
11. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Sinovac Biotech ... a leading provider of biopharmaceutical products in ... of its board of directors received on February 4, ... 2016, from a consortium comprised of PKU V-Ming ( ... Biomedicine Co., Ltd., CICC Qianhai Development ( Shenzhen ...
(Date:2/3/2016)... , Feb. 3, 2016  Discovery Laboratories, Inc. ... on developing aerosolized KL4 surfactant therapies for respiratory ... has approved an inducement award as a component ... its newly appointed President and Chief Executive Officer.  ... Committee on February 1, 2016 and granted as ...
(Date:2/3/2016)... ... February 03, 2016 , ... Aerocom, a world-leading supplier ... the North American healthcare market. , Aerocom Healthcare, LLC will be based in ... will provide new pneumatic tube systems or expand existing systems within the U.S. ...
(Date:2/3/2016)... , Feb. 3, 2016  Today, Symphony Technology ... AlphaImpactRx , a leading provider of primary research ... to IMS Health , a global information and ... offerings, capabilities and technologies will be integrated into IMS ... global primary market research capabilities. ...
Breaking Biology Technology:
(Date:2/1/2016)... 1, 2016  Wocket® smart wallet ( www.wocketwallet.com ) announces the launch ... Joey Fatone . Las Vegas , where Joey ... --> Las Vegas , where Joey appeared at the ... new video ad was filmed at the Consumer Electronics Show (CES2016) in ... booth to meet and greet fans. --> ...
(Date:1/25/2016)... -- Glencoe Software, the world-leading supplier of image data management ... the data management solution OMERO Plus for the newly ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... Phenotypic analysis measures the characteristics and behavior of cells, ... such as health and disease, the presence or absence ...
(Date:1/20/2016)... -- A market that just keeps on growing. Molecular ... in genomics knowledge. Learn all about it in this ... dynamic trends are pushing market growth and company valuations. ... - pathogen evolution - next generation sequencing - emergence ... of the role of genetic material in Disease and ...
Breaking Biology News(10 mins):